119 related articles for article (PubMed ID: 34864947)
1. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry.
Calafat M; Mañosa M; Ricart E; Nos P; Iglesias-Flores E; Vera I; López-Sanromán A; Guardiola J; Taxonera C; Mínguez M; Martín-Arranz MD; de Castro L; de Francisco R; Rivero M; Garcia-Planella E; Calvet X; García-López S; Márquez L; Gomollón F; Barrio J; Esteve M; Muñoz F; Gisbert JP; Gutiérrez A; Hinojosa J; Argüelles-Arias F; Busquets D; Bujanda L; Pérez-Calle JL; Sicilia B; Merino O; Martínez P; Bermejo F; Lorente R; Barreiro-de Acosta M; Rodríguez C; Fe García-Sepulcre M; Monfort D; Cañete F; Domènech E;
J Crohns Colitis; 2022 Jul; 16(6):946-953. PubMed ID: 34864947
[TBL] [Abstract][Full Text] [Related]
2. The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease.
Mc Gettigan N; Afridi AS; Harkin G; Lardner C; Patchett S; Cheriyan D; Harewood G; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Jun; 36(6):1231-1241. PubMed ID: 33515082
[TBL] [Abstract][Full Text] [Related]
3. [Neutrophil-lymphocyte ratio at 14th week predicts loss of response to 52-week infliximab therapy in patients with Crohn's disease].
Qian G; Hongxia D; Jin LI
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Apr; 40(4):453-458. PubMed ID: 32895126
[TBL] [Abstract][Full Text] [Related]
4. Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.
Cheng J; Hamilton Z; Smyth M; Barker C; Israel D; Jacobson K
Inflamm Bowel Dis; 2017 Oct; 23(10):1762-1773. PubMed ID: 28837517
[TBL] [Abstract][Full Text] [Related]
5. Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study.
Zeze K; Hirano A; Torisu T; Esaki M; Moriyama T; Umeno J; Kawasaki K; Fujioka S; Fuyuno Y; Matsuno Y; Kitazono T
Dig Dis Sci; 2021 Sep; 66(9):3124-3131. PubMed ID: 32920717
[TBL] [Abstract][Full Text] [Related]
6. Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.
Liefferinckx C; Minsart C; Toubeau JF; Cremer A; Amininejad L; Quertinmont E; Devière J; Gils A; van Gossum A; Franchimont D
Inflamm Bowel Dis; 2017 Aug; 23(8):1371-1381. PubMed ID: 28498153
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions.
Pauchard I; Nancey S; Hacard F; Williet N; Roblin X; Moussata D; Bérard F; Flourié B; Boschetti G
Dig Dis; 2018; 36(6):417-426. PubMed ID: 30130790
[TBL] [Abstract][Full Text] [Related]
8. Safety and Durability of Accelerated Infliximab Dosing Strategies in Pediatric IBD: A Single Center, Retrospective Study.
Gibson M; Subedi S; Barker DH; Masur S; Mallette MM; Lingannan A; Recinos Soto AA; Esharif D; Maxwell SH; Riaz MS; Herzlinger MI; Shalon LB; Cerezo CS; Kasper VL; Ross AM; Leleiko NS; Shapiro JM
J Pediatr Gastroenterol Nutr; 2023 Aug; 77(2):207-213. PubMed ID: 37084343
[TBL] [Abstract][Full Text] [Related]
9. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study.
Hahn GD; LeBlanc JF; Golovics PA; Wetwittayakhlang P; Qatomah A; Wang A; Boodaghians L; Liu Chen Kiow J; Al Ali M; Wild G; Afif W; Bitton A; Lakatos PL; Bessissow T
World J Gastroenterol; 2022 Sep; 28(33):4823-4833. PubMed ID: 36156919
[TBL] [Abstract][Full Text] [Related]
11. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
[TBL] [Abstract][Full Text] [Related]
13. Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease.
Theodoraki E; Orfanoudaki E; Foteinogiannopoulou K; Koutroubakis IE
Inflamm Bowel Dis; 2018 May; 24(6):1266-1271. PubMed ID: 29718260
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of serum concentrations of antibodies to infliximab: a new approach for predicting secondary loss of response in inflammatory bowel diseases.
Grasmeier MK; Langmann AF; Langmann P; Treiber M; Thaler MA; Luppa PB
Therap Adv Gastroenterol; 2021; 14():17562848211037849. PubMed ID: 34434255
[TBL] [Abstract][Full Text] [Related]
15. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
[TBL] [Abstract][Full Text] [Related]
16. Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics.
Colman RJ; Vuijk SA; Mathôt RAA; Van Limbergen J; Jongsma MME; Schreurs MWJ; Minar P; de Ridder L; D'Haens GRAM
Inflamm Bowel Dis; 2024 Jan; ():. PubMed ID: 38167922
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety.
Dipasquale V; Romano C
J Clin Pharm Ther; 2020 Dec; 45(6):1228-1234. PubMed ID: 32743840
[TBL] [Abstract][Full Text] [Related]
19. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study.
Wang X; Cao J; Wang H; Ye C
Med Sci Monit; 2019 Mar; 25():2257-2264. PubMed ID: 30917108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
